DiaMedica Therapeutics Inc is a biopharmaceutical company based in Hopkins, MN, dedicated to developing innovative therapies for individuals battling serious vascular diseases. With a primary focus on acute ischemic stroke (AIS), DiaMedica aims to revolutionize the treatment landscape for the 80% of stroke patients who currently have no therapeutic alternative, by improving collateral circulation within a 24-hour treatment window following a stroke.
The company's lead candidate, DM199, is a potential treatment for various health conditions characterized by low levels of the KLK1 protein. In addition to AIS, DiaMedica is also working on a treatment to reduce blood pressure and improve kidney function in patients with cardio-renal disease, aiming to restore normal levels of KLK1 protein to regulate blood flow, reduce inflammation, and maintain vascular homeostasis.
Generated from the website